Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy.
OBJECTIVE
Permanent seed implants are accepted treatment of early stage prostate cancer. Implant quality is assessed by post implant CT-based dosimetry but prostate contours on CT images are obscured by metallic seed artefact and edema. Outcome depends on implant quality, but perceived implant quality depends on accurate prostate contouring. This study documents inter observer variation in prostate contouring on post implant CT scans.


METHODS
Ten patients had implant dosimetry calculated on 4 copies of the post implant CT scan. Prostate contours from MRI-CT fusion were the gold standard for prostate edge identification. CTs were contoured by an experienced prostate brachytherapist matching CT images to the pre implant TRUS, and by 2 GU radiation oncologists experienced in conformal radiotherapy planning. Dosimetry was compared to that obtained using MRI-CT fusion in terms of D90 and V100.


RESULTS
Contours and dosimetry were not reproducible among the 3 observers. The V100's of the experienced brachytherapist differed from that of MRI-CT fusion by a mean of 2.4% compared to 9.1% and 4.4% for observers 1 and 2, and the D90 by a mean of 9.3 Gy compared to 30.3 and 14.4 Gy for observers 1 and 2.


CONCLUSIONS
Quality assessment of prostate brachytherapy based on 1 month post implant CT is difficult. This may obscure the dose-response relationship in brachytherapy as well as create problems for quality assurance in multicentre trials evaluating brachytherapy against standard modalities. Whenever possible, MRI-CT fusion should be employed to verify prostate contours post implant.
Crook
Juanita
J
Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. juanita.crook@rmp.uhn.on.ca
Milosevic
Michael
M
Catton
Pamela
P
Yeung
Ivan
I
Haycocks
Tara
T
Tran
Thao
T
Catton
Charles
C
McLean
Michael
M
Panzarella
Tony
T
Haider
Masoom A
MA
D001918:Brachytherapy / Q000592:standards*; D006801:Humans; D008297:Male; D015588:Observer Variation; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D011785:Quality Assurance, Health Care; D011879:Radiotherapy Dosage; D014057:Tomography, X-Ray Computed / Q000706:statistics & numerical data*